canadian diabetes association clinical practice guidelines chronic kidney disease in diabetes...
TRANSCRIPT
Canadian Diabetes Association Clinical Practice Guidelines
Chronic Kidney Disease in Diabetes
Chapter 29
Phil McFarlane, Richard E. Gilbert,
Lori MacCallum, Peter Senior
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
SCREEN regularly with random urine albumin
creatinine ratio (ACR) and serum creatinine for
estimated glomerular filtration rate (eGFR) DIAGNOSE with repeat confirmed
ACR ≥2.0 mg/mmol and/or eGFR <60 mL/min
DELAY onset and/or progression with glycemic and
blood pressure control and ACE-inhibitor or Angiotensin
Receptor Blocker (ARB)
PREVENT complications with “sick day management”
counselling and referral when appropriate
2013Chronic Kidney Disease (CKD) Checklist
Patients with DM 6-12X more likely to be hospitalized for CKD or End-stage renal disease (ESRD)
Public Health Agency of Canada (August 2011); using 2008/09 data from the Canadian Chronic Disease Surveillance System (Public Health Agency of Canada).
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Diabetes is #1 Cause of New Cases of ESRD
Public Health Agency of Canada (August 2011); using 2008/09 data from the Canadian Chronic Disease Surveillance System (Public Health Agency of Canada).
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
CKD in Diabetes
ACR ≥2.0 mg/mmol
and / or
eGFR <60 mL/min
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Diabetic Nephropathy
“ Progressive increase in proteinuria in people
with longstanding diabetes, followed by
declining function which can eventually lead to
End-Stage Renal Disease (ESRD)”
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Stages of Diabetic Nephropathy
Note: change in definition of microalbuminuria ACR ≥2.0 mg/mmol2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Screening and
Diagnosis of CKD in
Diabetes
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Beware of Transient Albuminuria
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
2
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Beware
of Other
Causes
of CKD
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
When to Consider Other Causes of CKD
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
2
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Care Gap Still Exists for Screening
Canadian Institute of Health Information – Diabetes Care Gap 2009
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
• Optimal glycemic control in type 1 and type 2
diabetes has been shown to reduce the development
and progression of nephropathy
Prevention of Diabetic Nephropathy
The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
34% RRR (p<0.04)
43% RRR(p=0.001)
56% RRR(p=0.01)
Primary Prevention Secondary Intervention
Solid line = risk of developing microalbuminuriaDashed line = risk of developing macroalbuminuria
DCCT: Reduction in Albuminuria
RRR = relative risk reductionCI = confidence interval
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
deBoer IH et al. Arch Intern Med 2011;171(5):412-420.
HR 1.92 (p<0.05)
HR 0.64(95% CI 0.40-
1.02)
Return to normoalbuminuria
Macroalbuminuria
HR = hazard ratioCI = confidence interval
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
EDIC: Continued Reduction in Albuminuria
EDIC: Early Glycemic Control Reduces Long-term Risk of Impaired GFR
Risk reduction with intensive therapy50%
(95% CI 18-69; p=0.006)
DCCT/EDIC Research Group. N Engl J Med 2011;365:2366-76.
After median 8.5 years post-trial follow-up
Aggregate Endpoint 1997 2007
Any diabetes related endpoint RRR: 12% 9% P: 0.029 0.040
Microvascular disease RRR: 25% 24% P: 0.0099 0.001
Myocardial infarction RRR: 16% 15% P: 0.052 0.014
All-cause mortality RRR: 6% 13% P: 0.44 0.007
Holman R, et al. N Engl J Med 2008;359.
UKPDS: Post-trial Monitoring “Legacy Effect”
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
New/worsening nephropathy, retinopathy
66
Cumulative incidence (%)
Follow-up (months)
HR 0.86 (0.77-0.97)p = 0.01 Standard
control
Intensive control
25
20
15
10
5
00 6 12 18 24 30 36 42 48 54 60
Intensive Standard HR p
Nephropathy/retinopathy (%) 9.4 10.9 0.86 0.01
Nephropathy (%) 4.1 5.2 0.79 0.006
Retinopathy (%) 6.0 6.3 0.95 NSAdapted from:ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.ADVANCE Collaborative Group. N Engl J Med 2008;358:24.
ADVANCE: Primary Microvascular Outcomes
Reducing Progression of Diabetic Nephropathy
• Optimal glycemic control (as shown)
• Optimal blood pressure control
• ACE-inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB)
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
ACE-inhibitor in T1DM with MAU Reduces Progression to Clinical Proteinuria
Laffel LM et al. Am J Med 1995;99(5):497-504.
Months of Therapy
Pro
po
rtio
n w
ith
Eve
nt
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Lewis EJ et al. N Engl J Med 1993;329:1456-62.
ACE-inhibitor in T1DM with Macroalbuminuria Reduces Renal Outcomes
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
ARB in T2DM with MAU reduces progression
0 3 6 9 12 15 18 21 240
5
10
15
20
Follow-up (months)
Inc
ide
nc
e o
f d
iab
eti
c n
ep
hro
pa
thy
(%
)
Parving et al. N Engl J Med 2001;345:870-8
Primary endpoint: Time to onset of diabetic nephropathy* (n=590)
*defined by persistent albuminuria in overnight specimens,with urinary albumin excretion rate <200 μg/min and ≥30% higher than baseline level
Placebo
Irbesartan 150mg
Irbesartan 300mg
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Brenner et al. N Engl J Med 2001;345:861-9
Cu
mu
lati
ve %
of
pat
ien
ts w
ith
eve
nt
Months240 12 36 48
Placebo
Losartan
Risk reduction = 16%
p=0.02
0
10
20
30
40
50
Primary endpoint: Time to doubling of serum creatinine, ESRD, or death (n=1513)
ARB in T2DM with Macroalbuminuria Reduces Renal Outcomes
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Lewis et al. N Engl J Med 2001;345:851-60
Primary endpoint: Time to doubling of serum creatinine,ESRD, or death (n=1,715)
Pat
ien
ts (
%)
0 6 12 18 24 30 36 42 48 54
Follow-up (mo)
60
0
10
20
30
40
50
60
70
Irbesartan
Amlodipine
Placebo
RRR 20%p=0.02p=NS
RRR 23%p=0.006
ARB in T2DM with Macroalbuminuria Reduces Renal Outcomes
Safe use of treatments in kidney
disease…..
• Check serum K+ and Cr– Baseline– Within 1-2 weeks of initiation or titration– During acute illness
If K+ becomes elevated or Cr >30% increase
Review therapy
Recheck serum K+ and Cr
Practical Tips: Potassium (K+) and Creatinine (Cr)
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
• Mild to moderate stable hyperkalemia– Counsel on a low potassium diet
– If persistent, consider adding non-potassium sparing
diuretics and/or oral sodium bicarbonate (in those with
metabolic acidosis)
– Consider temporarily holding or discontinuing ACEi, ARB or
Direct Renin Inhibitor (DRI)
• Severe hyperkalemia– Hold or discontinue ACEi, ARB or DRI
– Emergency management strategies
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Practical Tips: Potassium (K+) and Creatinine (Cr)
Counsel all Patients About
Sick Day Medication
List
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
See CPG Appendix 6 for therapeutic considerations
for renal impairment
2013
• Chronic, progressive loss of kidney function
• ACR persistently >60 mg/mmol
• eGFR <30 mL/min
• Unable to remain on renal-protective therapies due to
adverse effects such as hyperkalemia or a >30%
increase in serum Cr within 3 months of starting ACEi
or ARB
• Unable to achieve target BP (could be referred to any
specialist in hypertension)
When to Refer…..
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
1. In adults, screening for CKD in diabetes should be
conducted using a random urine ACR and a
serum creatinine converted into an eGFR [Grade D,
Consensus].
Screening should commence at diagnosis of
diabetes in individuals with type 2 diabetes and 5
years after diagnosis in adults with type 1
diabetes and repeated yearly thereafter.
Recommendation 1: Screening
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
A diagnosis of chronic kidney disease should be made
in patients with a random urine ACR ≥2.0 mg/mmol
and/or an eGFR<60 mL/min on at least two out of
three samples over a three month period [Grade D,
Consensus].
2013
Recommendation 1: Screening (continued)
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 2: Vascular Protection
2. All patients with diabetes and chronic kidney
disease should receive a comprehensive,
multifaceted approach to reduce cardiovascular
risk (see Vascular Protection, CPG Chapter 22) [Grade A, Level 1A].
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 3: Treatment
3. Adults with diabetes and CKD with either
hypertension or albuminuria should receive an
ACE inhibitor or an ARB to delay progression of
CKD [Grade A, Level 1A for ACE-inhibitor use in type 1 and type 2
diabetes, and for ARB use in type 2 diabetes; Grade D, Consensus, for ARB
use in type 1 diabetes].
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
4. People with diabetes on an ACE inhibitor or an ARB
should have their serum creatinine and potassium
levels checked at baseline and within 1 to 2 weeks
of initiation or titration of therapy and during times
of acute illness [Grade D, Consensus].
5. Adults with diabetes and CKD should be given a
“sick day” medication list that outlines which
medications should be held during times of acute
illness (see CPG Appendix) [Grade D, Consensus].
2013
Recommendation 4 and 5
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 6
6. Combination of agents that block the renin-
angiotensin-aldosterone system (ACE-inhibitor,
ARB, DRI) should not be routinely used in the
management of diabetes and CKD [Grade A, Level 1].
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 7: When to Refer
7. People with diabetes should be referred to a
nephrologist or internist with an expertise in chronic
kidney disease in the following situations:– Chronic, progressive loss of kidney function
– ACR persistently >60 mg/mmol
– eGFR<30 mL/min
– Unable to remain on renal-protective therapies due to
adverse effects such as hyperkalemia or a >30% increase in
serum creatinine within 3 months of starting an ACE-inhibitor
or ARB
– Unable to achieve target BP (could be referred to any
specialist in hypertension) [Grade D, Consensus]
CDA Clinical Practice Guidelines
www.guidelines.diabetes.ca – for professionals
1-800-BANTING (226-8464)
www.diabetes.ca – for patients